GSK Stock Recent News
GSK LATEST HEADLINES
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
Class Action Filed Against GSK plc (GSK) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138322&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138199&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's asthama drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138108&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138040&wire=1 or contact Joseph E. Levi, Esq.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In GSK To Contact Him Directly To Discuss Their Options
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138025&wire=1 or contact Joseph E. Levi, Esq.